FDG-PETの肺がんとリンパ節転移の最大標準化された取り込み値（SUVMAX）の関係

目的：FDG-PETおよびリンパ節転移の原発性肺癌のsuvmax間の関係を評価する。 方法と材料：被験者は、FDG-PETによって検査され、2004年10月から2008年1月の間に手術を受けた肺がんの合計66人の患者でした。平均68年。肺癌の病理学的サブタイプは、49の腺癌、11の扁平上皮癌、2つのアデノスクアマス癌、1つの大細胞癌、1つの小細胞癌、1つの小葉癌、1匹の粘膜皮膚癌で構成されていました。統計的に比較しました（1）リンパ節転移の有無にかかわらず肺癌の平均suvmaxを比較します（2）肺がんの中央値Suvmaxを使用して分類された肺がん群のより高いsuvmaxの間のリンパ節転移の頻度、および（3）肺がんのsuvmaxとリンパ節転移の頻度との関係、および（4）肺がんのsuvmaxと転移性リンパ節の数と病理学的n段階との間の相関を評価しました。 結果：リンパ節転移の有無にかかわらず症例間の肺癌のSUVmaxの平均の違いは統計的に有意でした（P = 0.00513）。リンパ節転移は、肺がん群のより低い肺がん群（7/33、21％）よりも高い肺がん群（17/33、52％）の方が、統計的に有意な差があるよりも頻繁に見られました。肺がんのsuvmaxが2.5未満の肺がんにはリンパ節転移はなく、肺がんのsuvmaxを持つ肺癌は12を超えるリンパ節転移の頻度が70％でした。肺がんのsuvmaxと、転移性リンパ節の数（ガンマ= 0.404、p = 0.001）と病理N期（ガンマ= 0.411、p = 0.001）の間には中程度の相関がありました。 結論：リンパ節転移の可能性は、原発性肺癌のSUVの増加とともに増加します。

PURPOSE: To evaluate the relationship between SUVmax of primary lung cancers on FDG-PET and lymph node metastasis. METHOD AND MATERIALS: The subjects were a total of consecutive 66 patients with lung cancer who were examined by FDG-PET and subsequently underwent surgery between October 2004 and January 2008. There were 41 males and 25 females, ranging in age from 45 to 83 years with an average of 68 years. The pathological subtypes of the lung cancers consisted of 49 adenocarcinomas, 11 squamous cell carcinomas, 2 adenosquamous carcinoma, 1 large cell carcinoma, 1 small cell carcinoma, 1 pleomorphic carcinoma and 1 mucoepidermoid carcinoma. We statistically compared (1) the mean SUVmax of lung cancer between the groups with and without lymph node metastasis (2) the frequency of lymph node metastasis between higher and lower SUVmax of lung cancer groups that were classified by using the median SUVmax of lung cancer, and (3) evaluated the relationship between the SUVmax of lung cancer and frequency of lymph node metastases, and (4) correlations between the SUVmax of lung cancer and number of the metastatic lymph nodes and pathological n stages. RESULTS: The difference in the average of the SUVmax of lung cancer between the cases with and without lymph node metastases was statistically significant (p = 0.00513). Lymph node metastasis was more frequently seen in the higher SUVmax of lung cancer group (17/33, 52%) than in the lower SUVmax of lung cancer group (7/33, 21%) with a statistically significant difference. There was no lymph node metastasis in lung cancers with an SUVmax of lung cancer less than 2.5, and lung cancers with an SUVmax of lung cancer more than 12 had a 70% frequency of lymph node metastasis. There were moderate correlations between SUVmax of lung cancer, and the number of the metastatic lymph nodes (gamma = 0.404, p = 0.001) and pathological n stage (gamma = 0.411, p = 0.001). CONCLUSIONS: The likelihood of lymph node metastasis increases with an increase of the SUV of a primary lung cancer.